Detalles de la búsqueda
1.
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Rheumatology (Oxford)
; 62(5): 1804-1813, 2023 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36018230
2.
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Ann Rheum Dis
; 80(4): 432-439, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33148701
3.
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Mod Rheumatol
; 29(5): 756-766, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30489177
4.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet
; 390(10093): 457-468, 2017 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-28629665
5.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5â years: integrated analysis of data from the global clinical trials.
Ann Rheum Dis
; 76(7): 1253-1262, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28143815
6.
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Rheumatology (Oxford)
; 56(1): 46-57, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28028154
7.
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Clin Rheumatol
; 39(7): 2127-2137, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048083
8.
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
Arthritis Care Res (Hoboken)
; 71(1): 71-79, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29696833
9.
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Arthritis Rheumatol
; 71(9): 1450-1459, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31385441
10.
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
RMD Open
; 5(2): e001040, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31673419
11.
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Arthritis Res Ther
; 21(1): 89, 2019 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30953540
12.
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Arthritis Care Res (Hoboken)
; 71(10): 1387-1395, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31112005
13.
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.
Drug Saf
; 41(5): 473-488, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29318514
14.
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.
Rheumatol Ther
; 5(1): 283-291, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29470834
15.
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
Adv Ther
; 35(10): 1535-1563, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30128641
16.
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.
RMD Open
; 2(2): e000262, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27493790
Resultados
1 -
16
de 16
1
Próxima >
>>